Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Michael_Severino
|
| gptkbp:employs |
over 200 people
|
| gptkbp:focusesOn |
genetic medicine
gene writing |
| gptkbp:foundedYear |
2018
|
| gptkbp:founder |
gptkb:Flagship_Pioneering
|
| gptkbp:fundedBy |
$230 million (2021 Series B)
|
| gptkbp:headquartersLocation |
gptkb:Somerville,_Massachusetts,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:logo |
Tessera Therapeutics logo.svg
|
| gptkbp:mission |
cure disease by writing and rewriting the code of life
|
| gptkbp:notableInvestment |
gptkb:Qatar_Investment_Authority
gptkb:SoftBank_Vision_Fund_2 gptkb:Fidelity_Management_&_Research_Company |
| gptkbp:parentCompany |
gptkb:Flagship_Pioneering
|
| gptkbp:platform |
gene writing
|
| gptkbp:researchInterest |
genetic diseases
therapeutic genome engineering |
| gptkbp:website |
https://www.tesseratherapeutics.com/
|
| gptkbp:bfsParent |
gptkb:Alexandria_Venture_Investments
gptkb:Osage_University_Partners |
| gptkbp:bfsLayer |
6
|
| http://www.w3.org/2000/01/rdf-schema#label |
Tessera Therapeutics
|